What PCSK9 inhibitors may mean for neurodegenerative diseases
Original source
PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human, Animal
A review examines how PCSK9 inhibitors, medicines used to lower cholesterol, might affect neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). It discusses possible effects on brain processes such as inflammation, amyloid-beta clearance and the blood-brain barrier, but says human genetic findings are complex and sometimes conflicting. More long-term clinical and laboratory research is needed.
Why this matters
The review may help guide research into whether PCSK9-related treatments have effects beyond cardiovascular health. It does not show that PCSK9 inhibitors treat or prevent ALS, and it does not change treatment decisions now.
Limitations and context
This is a review of existing evidence, not a new clinical trial. The review says adequately powered long-term studies with neurological, biomarker and imaging measures are still needed, along with studies using human-derived models.